Loading
Life sciences · Journal article
P a Herzen Journal of Oncology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Two rare clinical cases of synchronous gastric gastrointestinal stromal tumor (GIST) and locally advanced adenocarcinoma are presented. In both cases, complete pathological regression of gastric adenocarcinoma was achieved following different neoadjuvant therapy regimens. In the first case (74-year-old female patient D.), neoadjuvant chemotherapy with the FLOT regimen was administered for cT3N0M0 gastric cancer (stage IIB), followed by D2 gastrectomy. Complete pathological response was confirmed (ypT0N0, Becker grade 1a). Morphological examination incidentally revealed a subserosal GIST measuring 0.5 cm in diameter with absent mitotic activity and a progression risk of 0% (Miettinen 2006). In the second case (76-year-old male patient G.), within a clinical trial, neoadjuvant chemoradiotherapy (total dose 46 Gy with capecitabine and oxaliplatin) was delivered for cT3N1M0 gastric cancer (stage III), followed by D2 gastrectomy. Pathological examination demonstrated complete tumor regression (ypT0N0, Becker grade 1a) and identified a 1 cm GIST with a progression risk of 0%. The patient declined adjuvant chemotherapy and remains disease-free after 67 months of follow-up. These observations illustrate a rare combination of two tumors of distinct histogenesis in which complete pathological response of gastric adenocarcinoma to neoadjuvant treatment was achieved.